AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23592605
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ropivacaine + 5 µg sufentanil
Trial: 23592605
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg ropivacaine + 5 µg sufentanil
Trial: 23592605
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of ropivacaine
Trial: 17709798
Drug: Tamoxifen 1
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 1 mg/day
Trial: 24241787
Drug: Tamoxifen 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 5 mg/day
Trial: 8916481
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of exercise training (interval exercise with bicycle ergometer 15 minutes 5 times weekly, interval treadmill walking 10 minutes, and exercises 20 minutes, each 3 times weekly)
Trial: 7064017
Drug: Doxorubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (40 mg/m2) and cyclophosphamide (700 mg/m2) administered as pulse doses once every 3 weeks.
Trial: 31927549
Drug: Group TPVB
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group TPVB (20 mL of 0.25% ropivacaine)
Trial: 31927549
Drug: Group LAI
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group LAI (40 mL of 0.25% ropivacaine)
Trial: 30859959
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) antipsychotics
Trial: 23782126
Drug: 20 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day BH4
Trial: 21719096
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg, maximum 1000 mg per dose) administered intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years
Trial: 21494892
Drug: Oxycodone HCl
RxNorm normalized name: oxycodone HCl
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone HCl IR 10 mg
Trial: 17164971
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of assisted exercise (daily passive extension and flexion range-of-motion exercise of the upper and lower extremities)
Trial: 11843769
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit with leukocyte-depleting arterial line filter (HF group)
Trial: 22069289
Drug: vitD3 (140,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitD3 (140,000 IU monthly)
Trial: 19413683
Drug: Clonidine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.01 mg min(‐1) IV, max 0.1 mg, placebo SC)
Trial: 19413683
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg SC, placebo IV)
Trial: 9091692
Drug: Midodrine 10
RxNorm normalized name: midodrine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 10 mg, 3 times per day
Trial: 29253122
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (chemotherapy)
Trial: 29253122
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (chemotherapy)
Trial: 20485282
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (250 ml, day before procedure) followed by 2 liters PEG (day of procedure) - group 3
Trial: 1408297
Drug: Self-administered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered treatment
Trial: 12142115
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin (international normalized ratio 2 to 3)
Trial: 12142115
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg and clopidogrel 75 mg combination therapy
Trial: 7790321
Drug: Met‐depleting TPN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Met‐depleting TPN with 5‐FU (500 mg/body per day; total 4.0 g/body) for 7 days before surgery
Trial: 7790321
Drug: Conventional L‐methionine‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional L‐methionine‐containing TPN with 5‐FU
Trial: 31684880
Drug: Azospirillum (AL)
RxNorm normalized name: AL-034
DrugBank: AL-034 (DB17471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azospirillum (AL) with half dose of NP fertilizers (25 kg/ha N and 30 kg/ha P)
Trial: 31684880
Drug: Azotobacter (AV)
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azotobacter (AV) with half dose of NP fertilizers
Trial: 31684880
Drug: Azospirillum (AL)
RxNorm normalized name: AL-034
DrugBank: AL-034 (DB17471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azospirillum (AL) with half dose of NP fertilizers
Trial: 28173154
Drug: Extensive peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensive peritoneal lavage (10 l of saline)
Trial: 28173154
Drug: Standard lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lavage (≤2 l of saline)
Trial: 25460215
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose mCIMT (60 h)
Trial: 25460215
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose mCIMT (30 h)
Trial: 25460215
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose bimanual therapy (30 h)
Trial: 25460215
Drug: Bimanual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual therapy (full dose)
Trial: 23149871
Drug: Empagliflozin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (1 mg to 100 mg doses)
Trial: 28022576
Drug: TJ-107 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ-107 (2.5 g three times daily)
Trial: 16393192
Drug: Professional treatment
RxNorm normalized name: ANHYDROUS DEXTROSE 5 g in 20 g / CURCUMIN 4 g in 20 g / ICOSAPENT 3 g in 20 g / CHOLECALCIFEROL 2 g in 20 g TOPICAL GEL [SOUTH MOON Propolis Professional Treatment Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional treatment for drinking problems
Trial: 16393192
Drug: Broader treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broader treatment system including pretreatment assessment and additional forms of help
Trial: 16393192
Drug: Self-directed change
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed change during and following treatment
Trial: 15242012
Drug: 24 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g/d of resistant corn starch (RS)
Trial: 9066993
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg methylphenidate (MPH)
Trial: 29713147
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplementation (Aminoglutam®) administered twice a day for 4 weeks (96 kcal, 12 g amino acids, 0.18 g fat, 11.6 g carbohydrate, and vitamins B1, B6, and C)
Trial: 24990028
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity personalized physical training (32 weeks, twice a week, optional extra session once a week)
Trial: 1680791
Drug: Zidovudine administered
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine administered twice daily
Trial: 1680791
Drug: Zidovudine administered
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine administered four times daily
Trial: 6353433
Drug: Indoramin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (25 mg twice daily) plus hydrochlorothiazide (25 mg twice daily) or propranolol (40 mg once daily)
Trial: 31601947
Drug: Anti-beta1 adrenergic
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-beta1 adrenergic receptor antibody concentrations < median in STEMI patients ≤60 years
Trial: 31601947
Drug: Anti-beta1 adrenergic
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-beta1 adrenergic receptor antibody concentrations > median in STEMI patients ≤60 years
Trial: 29029033
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg)
Trial: 29029033
Drug: Rifaximin (1650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (1650 mg)
Trial: 16700802
Drug: Eberconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eberconazole 1% cream every 12 h for 4 weeks
Trial: 16700802
Drug: Miconazole 2%
RxNorm normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole 2% cream every 12 h for 4 weeks
Trial: 3583491
Drug: Miconazole 2%
RxNorm normalized name: MICONAZOLE 200MG SUPP/MICONAZOLE 2% CREAM PAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole 2% cream
Trial: 11283883
Drug: Lactulose/rhamnose solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose/rhamnose solution (1 mL/kg body weight) given at different time intervals after admission
Trial: 9207820
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of misoprostol (400 micrograms)
Trial: 9207820
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of misoprostol (400 micrograms)
Trial: 6111212
Drug: Atenolol 200
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 200 mg daily
Trial: 28627356
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy (AT) - 30 minutes, twice weekly for 6 months
Trial: 28627356
Drug: Land-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based therapy (LBT)
Trial: 23135868
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg/day (increased to 300 mg/day)
Trial: 11465651
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg/day
Trial: 12763375
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy after a short course of HBIg and lamivudine
Trial: 10797336
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline (100 ml, 2 g)
Trial: 1425642
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (5.76, 2.88 and 2.88 g per day of leucine, isoleucine and valine, respectively)
Trial: 31340094
Drug: Erdafitinib (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (8 mg per day in a continuous regimen)
Trial: 17555412
Drug: Ultrasonic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic treatment
Trial: 10459959
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice daily until labour, 600 mg at beginning of labour, and 300 mg twice daily for 7 days post partum)
Trial: 7639221
Drug: Sucralfate suspension
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate suspension 2 g BID
Trial: 2696630
Drug: Mitoxantrone containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone containing multi-drug chemotherapy
Trial: 2696630
Drug: Other malignancies
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other malignancies treatment
Trial: 2696630
Drug: Adriamycin or
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin or epirubicin combined with other drugs (control)
Trial: 20702754
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily for 8 days
Trial: 10771458
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg once daily for 6 days
Trial: 16700666
Drug: Narrow-band UV-B
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UV-B (NBUVB) plus 0.05% topical calcipotriol ointment
Trial: 14715387
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine 1 mg/ml
Trial: 14715387
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine 1 mg/ml plus naloxone 0.6 microg/ml
Trial: 9669007
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg granisetron (Group G)
Trial: 9669007
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg droperidol (Group D)
Trial: 9669007
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg granisetron plus 1.25 mg droperidol (Group GD)
Trial: 4061978
Drug: Albuterol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (180 micrograms)
Trial: 7636054
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg + Albuterol
Trial: 7636054
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg + Albuterol
Trial: 7636054
Drug: Cetirizine 20
RxNorm normalized name: cetirizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 20 mg + Albuterol
Trial: 28238711
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2‐90)
Trial: 28238711
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2‐90)
Trial: 24088368
Drug: Intensive Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Insulin Therapy (IIT) protocol presumed if median Glu₁ <6.44 mmol/L
Trial: 22069132
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with medication
Trial: 22069132
Drug: Medication (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (tricyclic antidepressants or selective serotonin reuptake inhibitors)
Trial: 17698578
Drug: self-administered paper-and-pencil
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-administered paper-and-pencil questionnaire
Trial: 15328251
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (1000 mg nightly for 14 days)
Trial: 11432623
Drug: High-dose platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose platinum (cisplatin and carboplatin)
Trial: 9492500
Drug: Low flow
RxNorm normalized name: high mallow flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow sevoflurane (0.5 l.min‐1 during pause)
Trial: 9138869
Drug: Goserelin injections
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin injections (3 doses of 3.6 mg subcutaneously at 4-week intervals) followed by hysteroscopic resection if fibroids remained submucous.
Trial: 30019265
Drug: Adapted physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted physical activity (APA) programme, 4 months of weekly classes of 45 min
Trial: 27965257
Drug: Intravenous secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous secukinumab 150 mg
Trial: 27965257
Drug: Intravenous secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous secukinumab 75 mg
Trial: 19223739
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel injection NK
Trial: 19223739
Drug: Taxol injection
RxNorm normalized name: Taxol Injectable Product
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taxol injection
Trial: 12622764
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (rabeprazole 20 mg b.d., rifabutin 300 mg once daily, levofloxacin 500 mg once daily for 7 days)
Trial: 12622764
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (rabeprazole 20 mg b.d., metronidazole 400 mg t.d.s., bismuth subcitrate 120 mg q.d.s., tetracycline 500 mg q.d.s. for 7 days)
Trial: 17285097
Drug: Citalopram (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20-40 mg daily)
Trial: 28716428
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin treatment (40mg atorvastatin)
Trial: 28716428
Drug: Low-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity statin treatment (20mg pravastatin)
Trial: 26928074
Drug: Investigational trivalent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with aluminum hydroxide
Trial: 26928074
Drug: Investigational trivalent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with MF59(®)
Trial: 22264496
Drug: Interview for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interview for Deterioration in Daily Living Activities in Dementia (IDDD)
Trial: 18555114
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker verapamil (100 microg injected into renal artery)
Trial: 16133638
Drug: Milk Basic
RxNorm normalized name: Milk Basic Protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk Basic Protein (MBP) 40 mg per day for 6 months
Trial: 12234091
Drug: modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified constraint-induced therapy (mCIT)
Trial: 12234091
Drug: regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: regular therapy (TR)
Trial: 12234091
Drug: no therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no therapy (CON)
Trial: 291771
Drug: Immunotherapy (BCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (BCG and allogenic acute myelomonocytic leukemic cells)
Trial: 26452709
Drug: Erythropoietin (40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (40,000 units subcutaneously once per week for a maximum of three doses)
Trial: 26452709
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride subcutaneously once per week for a maximum of three doses)
Trial: 22924372
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplements (1 gr daily for three months)
Trial: 19180855
Drug: Suspension seat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension seat
Trial: 17350342
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of antiepileptic drugs (AEDs)
Trial: 15249567
Drug: Emtricitabine 200
RxNorm normalized name: emtricitabine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine 200 mg once daily (plus stavudine placebo twice daily) (n = 286)
Trial: 15249567
Drug: Stavudine at
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine at standard doses twice daily (plus emtricitabine placebo once daily) (n = 285)
Trial: 3551551
Drug: Lormetazepam 1
RxNorm normalized name: lormetazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 1 mg for 7 nights
Trial: 3551551
Drug: Chlormethiazole 384
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole 384 mg for 7 nights
Trial: 27845635
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of daily isoniazid preventive therapy (IPT)